摘要
目的探讨疏血通联合艾地苯醌治疗脑梗死伴血管性认知障碍患者的效果,研究其对神经电生理指标和认知功能的影响。方法将2022年4月至2024年5月于开封市中心医院进行诊治的68例脑梗死伴血管性认知障碍患者纳入研究,按照随机数表法分为两组,均34例。对照组使用艾地苯醌治疗,研究组使用疏血通联合艾地苯醌治疗,比较两组神经电生理指标,使用简易精神状态检查量表(MMSE)、蒙特利尔认知评估量表(MoCA)比较两组治疗前后认知功能,使用美国国立卫生研究院卒中量表(NIHSS)、Barthel指数(BI)比较两组治疗前后神经功能及日常生活能力,同时比较两组不良反应(发热、恶心、腹泻、皮疹)发生率。结果治疗前,两组(δ+θ)/(α+β)比较,差异无统计学意义(P>0.05);治疗后,研究组(δ+θ)/(α+β)低于对照组,差异有统计学意义(P<0.05)。治疗前,两组在MMSE与MoCA评分上,差异无统计学意义(P>0.05);治疗后,研究组的MMSE与MoCA评分显著高于对照组,差异有统计学意义(P<0.05)。治疗前,两组的NIHSS与BI评分无统计学差异,差异无统计学意义(P>0.05);治疗后,研究组的NIHSS评分低于对照组,BI评分高于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率(2.94%)低于对照组(17.65%),差异有统计学意义(P<0.05)。结论疏血通配合艾地苯醌治疗脑梗死伴血管性认知障碍患者,可改善神经功能,提升认知能力和日常生活能力,调节神经电生理指标,且不良反应较少。
Objective To explore the effects of Shuxuetong combined with edaravone on patients with cerebral infarction accompanied by vascular cognitive impairment,and to study its influence on neurophysiological indicators and cognitive function.Methods Sixty-eight patients with cerebral infarction accompanied by vascular cognitive impairment treated at Kaifeng Central Hospital from April 2022 to May 2024 were included in the study.Patients were randomly divided into two groups,with 34 cases in each group.The control group received edaravone treatment,while the study group received Shuxuetong combined with edaravone.Neurophysiological indicators were compared between the two groups.Cognitive function was assessed before and after treatment using the Mini-Mental State Examination(MMSE)and the Montreal Cognitive Assessment(MoCA).Neurological function and daily living abilities were compared before and after treatment using the NIH Stroke Scale(NIHSS)and the Barthel Index(BI).The incidence of adverse reactions(fever,nausea,diarrhea,rash)was also compared between the groups.Results Before treatment,there was no statistically significant difference in the ratio of(δ+θ)/(α+β)between the two groups(P>0.05).After treatment,the ratio in the study group was lower than that in the control group,with statistical significance(P<0.05).There was no significant difference in MMSE and MoCA scores between the two groups before treatment(P>0.05).However,after treatment,the MMSE and MoCA scores in the study group were significantly higher than those in the control group(P<0.05).Pre-treatment NIHSS and BI scores showed no significant differences between the two groups(P>0.05).After treatment,the NIHSS score in the study group was lower,and the BI score was higher than in the control group,with statistical significance(P<0.05).The incidence of adverse reactions was lower in the study group(2.94%)than in the control group(17.65%),showing statistical significance(P<0.05).Conclusion The combination of Shuxuetong and edaravone in treating patients with cerebral infarction accompanied by vascular cognitive impairment can improve neurological function,enhance cognitive abilities and daily living capabilities,and regulate neurophysiological indicators,with fewer adverse reactions.
作者
周美琴
ZHOU Meiqin(Department of Neurology,Kaifeng Central Hospital,Kaifeng Henan 475000,China)
出处
《临床研究》
2025年第3期125-128,共4页
Clinical Research
关键词
脑梗死伴血管性认知障碍
疏血通
艾地苯醌
经电生理指标
认知功能
Cerebral infarction with vascular cognitive impairment
Shuxuetong
Edaravone
Neurophysiological indicators
Cognitive function
